Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.5M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$171M |
Are VivoSim Labs Insiders Buying or Selling?
VivoSim Labs (VIVS) has had 1 insider transaction in the past 90 days, all buys — insider buying is generally read as a bullish signal. The most recent was Lialin Tony Serge, who bought 10,000 shares at $0.28 on August 31, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the VIVS AI Score. For government officials trading this stock, see VIVS congressional trading.
Recent VivoSim Labs Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Lialin Tony Serge | Aug 31, 2026 | Buy | 10,000 | $0.28 | $2,800 |
| David Gobel | Nov 17, 2025 | Sell | 3,266 | $2.24 | $7,300 |
Frequently Asked Questions: VivoSim Labs Insider Trading
In the past 90 days, VivoSim Labs insiders have made 1 buy and 0 sells. The net buying may indicate insider confidence in the company’s outlook.
The most recent sale was by David Gobel who sold 3,266 shares on November 17, 2025. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Lialin Tony Serge has bought the most VIVS stock in the last 2 years, with a total value of $2,800.
Gobel David has sold the most VIVS stock in the last 2 years, with a total value of $7,300.
The total value of insider transactions for VivoSim Labs in the last 2 years is negative, amounting to -$4,500. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
